FDA gives go-ahead to ST2 biomarker assay

Candace Stuart | December 16, 2011 | Cardiovascular Business | Heart Failure

Critical Diagnostics' Presage ST2 Assay, a cardiac biomarker assay that can be used in the prognosis of patients with chronic heart failure, was cleared by the FDA Dec. 15.

The prognostic tool, which measures soluble ST2 levels in blood, received CE mark in Europe earlier this year.

ST2 is a cardiac biomarker that has been shown to be associated with adverse cardiac remodeling and fibrosis, the company stated. Its presence may indicate MI, ischemia or worsening heart failure.

Candace Stuart, Contributor

Around the web

Health Imaging

Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

FDA gives go-ahead to ST2 biomarker assay

Related Content

Around the web